These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 26857783)
1. Effects of UGT1A1*6, UGT1A1*28, and ABCB1-3435C>T polymorphisms on irinotecan induced toxicity in Chinese cancer patients. Yan L; Wang XF; Wei LM; Nie YL; Liu JY; Zhang LR Int J Clin Pharmacol Ther; 2016 Mar; 54(3):193-9. PubMed ID: 26857783 [TBL] [Abstract][Full Text] [Related]
2. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events]. Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029 [No Abstract] [Full Text] [Related]
3. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients. Gao J; Zhou J; Li Y; Lu M; Jia R; Shen L Med Oncol; 2013; 30(3):604. PubMed ID: 23686699 [TBL] [Abstract][Full Text] [Related]
4. UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients. Peng H; Duan Z; Pan D; Wen J; Wei X Clin Lab; 2017 Sep; 63(9):1339-1346. PubMed ID: 28879724 [TBL] [Abstract][Full Text] [Related]
5. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity. Biason P; Masier S; Toffoli G J Chemother; 2008 Apr; 20(2):158-65. PubMed ID: 18467239 [TBL] [Abstract][Full Text] [Related]
6. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Onoue M; Terada T; Kobayashi M; Katsura T; Matsumoto S; Yanagihara K; Nishimura T; Kanai M; Teramukai S; Shimizu A; Fukushima M; Inui K Int J Clin Oncol; 2009 Apr; 14(2):136-42. PubMed ID: 19390945 [TBL] [Abstract][Full Text] [Related]
7. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238 [TBL] [Abstract][Full Text] [Related]
8. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities. Fakih MG; Ross ME; Starostik P Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105 [TBL] [Abstract][Full Text] [Related]
9. Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients. Gao J; Zhou J; Li Y; Peng Z; Li Y; Wang X; Shen L Med Oncol; 2013; 30(3):630. PubMed ID: 23783485 [TBL] [Abstract][Full Text] [Related]
10. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis. Liu D; Li J; Gao J; Li Y; Yang R; Shen L BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434 [TBL] [Abstract][Full Text] [Related]
11. Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. Hu ZY; Yu Q; Zhao YS Eur J Cancer; 2010 Jul; 46(10):1856-65. PubMed ID: 20335017 [TBL] [Abstract][Full Text] [Related]
12. [Examination of UGT1A1 polymorphisms and irinotecan-induced neutropenia in patients with Colorectal cancer]. Teruya T; Nakachi A; Shimabukuro N; Toritsuka D; Azuma Y; Hanashiro K; Nishiki T; Ota M; Shimabuku M; Shiroma H Gan To Kagaku Ryoho; 2015 May; 42(5):585-9. PubMed ID: 25981652 [TBL] [Abstract][Full Text] [Related]
13. Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms. Xu JM; Wang Y; Ge FJ; Lin L; Liu ZY; Sharma MR World J Gastroenterol; 2013 Jun; 19(24):3899-903. PubMed ID: 23840132 [TBL] [Abstract][Full Text] [Related]
14. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Kweekel D; Guchelaar HJ; Gelderblom H Cancer Treat Rev; 2008 Nov; 34(7):656-69. PubMed ID: 18558463 [TBL] [Abstract][Full Text] [Related]
15. UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis. Zhang X; Yin JF; Zhang J; Kong SJ; Zhang HY; Chen XM Cancer Chemother Pharmacol; 2017 Jul; 80(1):135-149. PubMed ID: 28585035 [TBL] [Abstract][Full Text] [Related]
16. Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens. Yang C; Liu Y; Xi WQ; Zhou CF; Jiang JL; Ma T; Ye ZB; Zhang J; Zhu ZG Drug Des Devel Ther; 2015; 9():3677-83. PubMed ID: 26229432 [TBL] [Abstract][Full Text] [Related]
17. Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan. Lu YY; Huang XE; Wu XY; Cao J; Liu J; Wang L; Xiang J Asian Pac J Cancer Prev; 2014; 15(7):3335-41. PubMed ID: 24815493 [TBL] [Abstract][Full Text] [Related]
18. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391 [TBL] [Abstract][Full Text] [Related]
19. UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians. Cheng L; Li M; Hu J; Ren W; Xie L; Sun ZP; Liu BR; Xu GX; Dong XL; Qian XP Cancer Chemother Pharmacol; 2014 Mar; 73(3):551-60. PubMed ID: 24448639 [TBL] [Abstract][Full Text] [Related]
20. [Study of irinotecan-induced toxicity and its correlation to UGT1A1 gene promoter polymorphisms]. Li H; Huang H; Liu JH Zhonghua Fu Chan Ke Za Zhi; 2011 Dec; 46(12):888-91. PubMed ID: 22333276 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]